CEO Seung-Yong Sung of Shaperon Co., Ltd. (pictured) received the '2025 Korea Management Award' in the CEO-Research and Development category. This marks the fourth consecutive year.

Shaperon's 'Multi Nanomab' is a tenth the size of existing antibodies and is manufactured in a single-chain form, innovatively overcoming challenges such as quality and side effect risks due to aggregate formation, which were obstacles for existing bispecific antibodies. This presents a new paradigm in the development of new drugs for cancer and infectious diseases by enhancing manufacturing quality stability, simplifying production processes, and reducing costs.

Shaperon's flagship pipeline, 'Pafrilimab,' is the world's first nanomab-based bispecific antibody targeting both PD-L1 and CD47, key pathways in cancer immune evasion. It demonstrated excellent anticancer efficacy against refractory cancer in animal experiments. Notably, the anemia side effect caused by red blood cell hemolysis, common in competing bispecific antibodies, did not appear in monkey studies, increasing the likelihood of clinical success.

The global bispecific antibody and antibody-drug conjugate (ADC) market is projected to grow at an average annual rate of 18% from KRW 13 trillion (approximately USD 10 billion) in 2025 to 2035. However, only about 20 bispecific antibodies and 10 ADCs have been approved for use.

Shaperon's nanomab is fundamentally different from the traditional four-chain structure of conventional antibodies, as it features a single-chain structure that fundamentally blocks the risk of aggregation. It is recognized as the world's first innovative single-chain-based bispecific antibody platform. Shaperon has registered major patents such as 'PD-L1 Target Nanomab' and 'PD-L1XCD47 Bispecific Nanomab' in key domestic and international markets, and its core technology for nanomab development has been published in international academic journals, establishing it as a global platform technology.

Shaperon has developed a full-cycle development infrastructure based on an antibody library produced at its proprietary alpaca farm, encompassing antigen production, immunization, library construction, clone acquisition through the Hera system, optimization of humanization and affinity, mass production, and immunological performance evaluation, thereby enhancing its global competitiveness.

Popular News